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Abstract 
Background: Urine 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) is a specific biomarker 
of oxidative stress. We evaluated a modified LC-MS/MS assay for urine 8-oxodG and 
determined biological variation in healthy adults.  
Method: Untreated urine was injected into an isocratic LC-MS/MS system (positive-ion 
MRM mode). Urine 8-oxodG in 51 healthy volunteers was measured; within- and between- 
day variations in 23 healthy volunteers were investigated. 
Results: Dose-response was linear to 452nmol/L; limit of detection=2.3nmol/L; within-run 
and between-run CVs were <3.0% and <4.7%, respectively; recovery=97%-101%; 
accuracy=97.7-103.5%. Urine 8-oxodG (median, mean [SD]): 1.70, 1.70[0.60]nmol/mmol 
creatinine (n=51). Men had higher (p=0.027) levels than women matched for age and body 
mass index: mean (SD), 1.90[1.60]; n=26 vs. 1.50[0.55];n=25. Within- and between-day 
variations were wide but random. No significant differences were seen overall across four 
time-points within one day (p=0.407) or at the same time-point across five consecutive days 
(p=0.381). 
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Conclusions: The method has advantages of speed and relative simplicity as it does not 
require sample pre-treatment for 8-oxodG extraction, the use of internal standard or gradient 
LC elution and has high linearity, specificity, precision and recovery. Biological variation in 
urine 8-oxodG is wide, but no within- or between-day differences at the group level were 
seen in healthy adults. 
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1. Introduction 
Guanine is the most easily oxidized nucleotide base, and its oxidation forms 8-oxo-
7,8-dihydro-2’-deoxyguanosine (8-oxodG, also known as 8-OHdG) [1,2]. Measurement of 8-
oxodG in DNA is a marker of oxidation-induced damage and, possibly, cancer risk, but 8-
oxodG measurement in cells is problematical due to post-sampling changes and artifact [2-4]. 
Measurement of 8-oxodG in urine is more straightforward. Extracellular 8-oxodG is excreted 
in urine without further metabolism. It is stable in urine, and levels are not affected directly 
by diet or cell death [2-4]. The origin of 8-oxodG in urine is not clear, but it is believed to be 
from sanitation of the nucleotide pool [2]. This makes urine 8-oxodG a potentially specific 
and robust biomarker of ‘whole body’ oxidative stress [4-8].  
Concentrations of 8-oxodG in human urine can cover a wide range due to the high 
variation in water content of urine, but are generally in the low nanomolar range [9].  At such 
low concentrations it is necessary to use an analytical technique that has a low limit of 
detection (LOD) and wide measuring range, as well as high specificity and precision. High-
performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) offers a 
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sensitive and specific tool for 8-oxodG measurement. Published LC-MS/MS methods for 
urine 8oxo-dG generally employ a sample pre-treatment step, often sold phase extraction, and 
require the use of an isotopic internal standard to correct for loss during this step [10,11]. In 
addition, the HPLC separation preceding entry to the spectrometer is usually by gradient 
elution [10,11].  The sample workup, internal standard and gradient requirements add to cost 
and time of analysis. Moreover, and importantly, published data on normal biological 
variation of urine 8-oxodG are lacking, making it difficult to interpret urine 8-oxodG data 
from clinical studies and intervention trials.   
In this study, a relatively simple, isocratic elution, direct injection HPLC-ESI/MS/MS 
method for urine 8-oxodG was evaluated in relation to analytical performance characteristics 
(linearity, precision, recovery, limit of detection). In addition, urine 8-oxodG in a sample of 
healthy men and women in our local population was determined, and biological variation 
(within- and between- day) in urine 8-oxodG in healthy subjects was investigated. We also 
measured, in pilot study, urine 8-oxodG in a small number of newly diagnosed cancer 
patients to explore disease related effects on 8-oxodG. 
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2. Materials and methods 
2.1. Chemicals  
8-oxodG (listed in product catalogue as 8-hydroxy-2’-deoxyguanosine) and 
ammonium acetate (Sigma Ultra) were purchased from Sigma (Sigma-Aldrich Inc., St. Louis, 
MO). Glacial acetic acid (AR grade) and acetonitrile (Hipersolv for HPLC) were from BDH 
(VWR International Ltd., Poole, UK). Water was of Milli-Q quality (18.2MΩ.cm). 
Standard samples or calibrators and controls: a stock standard solution of 8-oxodG was 
prepared in a small quantity of water. From this stock solution, the exact concentration of an 
aqueous diluted solution was determined by a Beckman Coulter DU Series 700 UV/Vis 
Scanning Spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) (ε 12,300 at 245nm) 
[12]. The stock and the diluted solutions were stored at -80°C. A solution of 1,127nM  in 
water was prepared weekly from the diluted solution and stored at 4°C for routine use and 
used daily to prepare working calibrators (0.0, 7.1, 14.1, 28.2, 56.5, 113.0nM) in thawed, 
pooled urine (stored at -80°C) from apparently healthy subjects.  Three control samples, 
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prepared by spiking the pooled urine with appropriate amounts of standard, were made, 
stored at -80°C, and thawed for use as needed. 
2.2. Urine samples, calibrators and controls 
Mid-stream urine samples were collected and stored at -80°C. Calibrators were 
prepared freshly each time by spiking known amounts of 8-oxodG standard into freshly 
thawed pooled urine. All test samples, calibrators and controls were vigorously mixed, 
sonicated for one min, and then centrifuged at 10,000g for 5min. A 25-µl sample of clear 
supernatant of each calibrator, control or test sample was directly injected into the HPLC-
ESI/MS/MS system.  
2.3. HPLC-ESI/MS/MS analysis  
HPLC separation was achieved using a Chromolith Performance RP-18e column 
(4.6mm ID x 100mm L, particle size: 2µm x 13nm pore) (Merck KGaA, Darmstadt, 
Germany) secured by a guard cartridge (C18, 3mm ID x 4mm L) (Phenomenex, Torrance, 
CA). The freshly prepared isocratic mobile phase was a solution of ammonium acetate 
(10mM, adjusted to pH 4.3 with acetic acid) and acetonitrile (96.4:3.6 in volume). The 
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solution was filtered through a 0.22-µm Millipore filter (Millipore Corporation, Bedford, MA) 
before use. With an integrated diverting valve installed in the spectrometer, only the eluate 
fraction of 8-oxodG was delivered into the spectrometer, the rest of the LC eluate was 
diverted to waste. Peak separations were done at a flow rate of 0.5ml/min for 10.0min (0–
7.5min eluate going to waste, 7.5–10.0min eluate going to the mass spectrometer), followed 
by a wash period of 6.0min at 2ml/min, washing with the same mobile phase. The HPLC 
system (Agilent 1100 Series, quaternary pump, G1311A and micro vacuum degasser, 
G1379A, Agilent Technologies Inc., Waldbronn, Germany), equipped with a non-
thermostatted well-plate autosampler (G1313A), was linked to a 3200 QTRAP mass 
spectrometer from Applied Biosystems/MDS Sciex (MDS Inc., Concord, ON, Canada). 
MS/MS analysis was performed in positive ion mode with a TurboIonSpray source. The 
spectrometer was first optimized by infusion of an 8-oxodG standard in water (7.0µM), using 
the integrated syringe pump (flow rate at 5µl/min). Both calibration and sample data were 
obtained by multiple reaction monitoring (MRM) acquisition: precursor ion ([M+H]+ at m/z 
284, Q1),  product ion (at m/z 168, Q3). The product ion was quantified using dwell time 
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500ms/channel with unit mass resolution for Q1 and Q3. The source parameters were set as 
follows: curtain gas (nitrogen), 12.0psi; collision gas (nitrogen), medium, ionspray voltage, 
5500V; temperature, 375°C; ion source gas (air) 1, 11.0psi; ion source gas (air) 2, 32.0psi; 
and interface heater, on. The parameters for the optimized compound were: declustering 
potential, 26.0V; entrance potential 3.5V; collision energy, 19.0eV; and, collision cell exit 
potential, 3.9V. All data were acquired and processed by Analyst Software 1.4.2 (MDS Inc., 
Concord, ON, Canada). 
2.4. Limit of detection, lower limit of quantification and ion suppression effects 
The absolute limit of detection (LOD) for the MS detector was defined as three times 
the signal-to-noise ratio of the 8-oxodG standard solution in water. In the absence of 8-
oxodG-free urine samples, LOD in urine matrix, the ‘true LOD’ of the assay, was calculated 
as follows: six calibration curves (y = mx + b) were constructed after subtracting the 8-oxodG 
urinary basal peak areas from the areas determined for each calibrator. LOD in urine matrix 
was calculated as twice the SD of the intercept, b, of the six calibration curve divided by the 
average slope, m. The lower limit of quantification (LOQ) for 8-oxodG in urine was assessed 
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by calculating 4 times SD of b, divided by m, from the calibration curves. The system was 
also tested for ion suppression effects at the critical elution time of 7-10min during method 
development [13].  
2.5. Precision, recovery and accuracy 
Precision was checked with three 8-oxodG-spiked pooled urine controls (spiked levels 
at 7.1, 14.1 and 56.5nM) which were stored at -80°C along with subject samples until 
analysis. Within-day precision was performed by 6 replicate samples tested within one day. 
Between-day precision was tested over 6 different days. Recovery of 8-oxodG was assessed 
in urine by addition, to normal pooled urine, of 8-oxodG in three different concentrations (7.1, 
28.3, 56.5nM), with each tested 6 times and in parallel with the same amounts added to water. 
Mean recovery (%) was estimated from the 8-oxodG concentration measured in urine divided 
by those measured in water, while accuracy was assessed from the concentration found in 
urine divided by the nominal (expected) concentration. The detection reproducibility in a 
urine sample under measuring conditions was also tested using an 8-oxodG control 
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containing a spike of 14.1nM 8-oxodG. This was left at room temperature and measured 
every 20 samples over the course of almost 24 hours. 
2.6. Subjects and experimental design 
Fifty one apparently healthy, non-obese Chinese adults, all non-smokers, were 
recruited with their informed consent. There were 26 men [mean (SD), age (y): 39.5(6.7); 
BMI (kg/m2): 22.6(2.4)] and 25 women [age: 38.0(8.3); BMI: 20.5(2.1)]. All procedures 
involving subjects complied with the Declaration of Helsinki (revised 2008). 
 For the investigation of the biological variation of urine 8-oxodG, the work was 
divided into 3 parts: (1) male to female differences study (n=51); (2) within-day variation 
study for each individual and overall for the group (n=23); and (3) day-to-day variation study 
for each individual and overall for the group (the same 23 subjects). These 23 subjects 
comprised 11 males [mean (SD), age (y): 38.1(5.1); BMI (kg/m2): 22.8(2.2)] and 12 females 
[age: 37.3(7.7); BMI: 20.7(2.2)]. From each subject repeated samples of mid-stream urine 
were collected into plain bottles as follows:   
i. For male/female differences study:  samples of first voided urine in the morning were 
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collected, with samples collected on the same day for all 51 subjects. 
ii. Within-day variation: four urine samples from each of the 23 subjects were collected 
over the course of a single day; the times of collection were: morning (first-voided 
urine); 1:00-2:00 pm; 6:00-7:00 pm; the last-voided urine before sleep. 
iii. Between-day variation: samples of first-voided urine were collected from each of the 23 
subjects on five consecutive days. 
All urine samples were stored at 4oC at the point of collection. On arrival in the 
laboratory, urine was centrifuged at 3,500g for 15min, and clear urine was aliquoted and 
stored at -80oC until needed. On the day of analysis, thawed urine was vortex mixed, 
sonicated for one minute and centrifuged at 10,000g for 5min, then 25µl of urine was injected 
directly into the LC-MS/MS system without further pre-treatment.  
To explore disease-related effects on urine 8-oxodG, we also performed a very 
preliminary pilot study in which 8-oxodG in urine collected from 11 newly diagnosed, 
consenting, cancer patients immediately prior to their beginning treatment was measured. 
2.7. Creatinine determination 
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Urine creatinine concentration was measured on the day of collection using a Dade 
Dimension RxL analyzer (Dade Behring Inc., Newark, NJ) and a kinetic Jaffe method for 
creatinine kit (Dade Behring, Milton Keynes, UK). 
2.8. Data analysis 
  Data were performed using Graphpad Prism, version 3.0 (San Diego, CA).  
Distribution of data was tested for normality before analysis. The unpaired t-test was used to 
investigate male/female differences in urine 8-oxodG, and to compare results in healthy 
subjects and cancer patients. Pearson’s correlation was used to investigate the relationship of 
urine 8-oxodG with age and BMI.  Biological variation was investigated using repeated 
measures analyses of variance and Bonferroni multiple comparison post-test. Male-female 
difference in biological variation was investigated by the Mann-Whitney test. The total 
analytical variation (CVA) was calculated from the individual CVs of 8-oxodG and creatinine 
assays, using the formula: [(CV8-oxodG)2 + (CVcreatinine)2]1/2. The mean±2SD (n=51) was set as 
a preliminary reference range for urine 8-oxodG. The total between-individual coefficient of 
variation (CVTB) of urine 8-oxodG was obtained by first calculating average values per 
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individual and then calculating standard deviation and mean of these individual averages. 
CVTB is the sum of the overall biological between-individual CV (CVBB) and the CVA.  So, 
CVBB was calculated as follows: CVBB = [(CVTB )2 - (CVA)2]1/2. The total within-individual 
CV (CVTW) of urine 8-oxodG was obtained by calculating the average of individual CV, 
which was obtained from standard deviation and mean per individual. CVTW is the sum of the 
overall biological within-individual CV (CVBW) and the CVA.  Hence, CVBW was calculated 
as follows: CVBW = [(CVTW)2 – (CVA)2]1/2. For biological variation information to be of any 
real value, the variance of a constituent must be homogeneous.  Index of heterogeneity was 
used to reach a quick decision on whether the within-individual variances showed 
heterogeneity.  The index of heterogeneity is the ratio of observed CVTW to theoretical CV, 
which is [2/(n-1)]1/2 where n is the average number of specimens collected per individual.  
The standard deviation of the difference between this ratio and its expected value of unity 
under the hypothesis of no heterogeneity of the true with subject variances is 1/(2n)1/2. It may 
be concluded that significant heterogeneity is present if the ratio differs from unity by at least 
twice this standard deviation [14]. The desirable analytical goal for imprecision was set at 0.5 
Biological variation in urine 8-oxodG by direct LCMSMS 
 
15
CVBW [14]. The index of individuality was calculated as CVBW/CVBB and was used to 
evaluate the utility of population based reference values.  When the index of individuality is 
less than 0.6, conventional population based reference values are of very limited value in the 
detection of unusual (or changed) results for a particular individual. Repeated sampling with 
comparison of the measured difference with reference change value may be superior to 
reference intervals for clinical interpretation at the individual level. In contrast, when index of 
individuality is more than 1.4, observed values can be compared usefully with reference 
values [14]. The reference change value (RCV), i.e., the change in a result that makes it 
significantly different from a previous result with p<0.05, was calculated as follows: RCV = 
2.8 x [(CVBW)2 + (CVA)2)]1/2 [14]. 
3. Results 
Typical chromatograms of 8-oxodG, including one investigating possible ion 
suppression effect, are shown in Fig. 1. The single, near symmetrical peak obtained indicates 
good LC resolution of 8-oxodG. No evidence of interaction or competition with other ions 
was seen, as evidenced by absence of ion suppression around the 8-oxodG peak eluate. A 
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linear dose response was obtained over a wide range (7-452nM). A typical calibration line is 
shown in Fig. 2.  
Figures 1 and 2 near here 
The absolute LOD, the ‘true’ LOD and LOQ (in urine) were 1.8, 2.3 and 4.6nM, 
respectively.  Water was used as the blank sample since normal urine contains 8-oxodG. To 
determine the absolute LOD, various amounts of 8-oxodG prepared in water were injected to 
obtain a peak with signal to noise ratio >3 [Fig. 3]. Within-day and between-day CVs (n=6 
for each of three 8-oxodG concentrations, 7.1, 14.1 and 56.5nM) were, respectively, 0.4-3.0% 
and 2.5-4.7% [Table 1]. Mean recovery and relative accuracy of 8-oxodG in the assay were, 
respectively, 97.1-101.0% and 97.7-103.5% across three different 8-oxodG concentrations 
(7.1, 28.3 and 56.5nM, n=6 for each) [Table 1]. The reproducibility (CV) of 8-oxodG 
measurement in a urine sample kept at room temperature and measured repeatedly over a 24 
hour period was 6.5% (n=5). The within-run and between-run CVs of urinary creatinine assay 
were 1.7-1.9% and 1.6-2.2%, respectively (n=6 for each). The desirable analytical goal for 
imprecision (0.5 x CVBW) for creatinine-standardized urinary 8-oxodG analysis was 
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estimated to be 9.1% or better.  Using the largest CVs of 8-oxodG and creatinine controls, the 
total CVA was found to be 5.6%. These figures for linearity, precision, recovery and LOD 
meet analytical goals and compare well with published methods (see discussion section).  
Figure 3 near here 
Table 1 near here 
 Urine 8-oxodG results of our 51 subjects are presented in Table 2. Urine 8-oxodG 
(nmol/mmol creatinine) in men was slightly but significantly (p=0.027) higher than in women.  
No significant correlation was seen between urine 8-oxodG and age (r2=0.006; p=0.592) or 
between urine 8-oxodG and BMI (r2=0.002; p=0.783) (data not shown).   
Table 2 near here 
 Individual variations, both within- and between-day, were wide [Fig. 4], however no 
statistically significant differences in urine 8-oxodG were seen in the group overall in 
samples collected at four different time-points within the same day. Urine 8-oxodG results 
(mean (SD), n=23 for each) for first voided morning urine and for urine collected at midday, 
evening and before sleep were, respectively, 1.7(0.52), 1.6(0.61), 1.7(0.65) and 1.6(0.61) 
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nmol/mmol creatinine (P>0.05). In samples collected at the same time-point over 5 
consecutive days biological variation was also wide, but no statistically significant between-
day differences were seen in the group overall. Mean (SD) urine 8-oxodG results were: 
Monday 1.6(0.57); Tuesday 1.5(0.50); Wednesday 1.6(0.52); Thursday 1.6(0.51); Friday 
1.5(0.54) nnol/mmol creatinine (P>0.05).   
Figure 4 near here 
  The total within-individual CV (CVTW) of all subjects was 19.1%.  The CVBW (overall 
biological within-individual CV) was 18.3%.  When results were compared for gender, no 
statistically significant difference in CVBW between males and females was detected (p=0.131) 
although the CVBW in males (15.1%) was smaller than females (20.7%). The total between-
individual CV (CVTB) of all subjects was 31.3%.  The CVBB (overall biological between-
individual CV) was 30.8%.  The CVBB in males (24.8%) was smaller than in females (36.7%) 
but this difference was not statistically significant.  
  The index of heterogeneity of all subjects, males and females was, respectively, 0.36, 
0.30 and 0.40. In each case this is less than twice of the corresponding standard deviations of 
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the difference between the index of heterogeneity and their expected value of unity under the 
hypothesis of no heterogeneity of the true with subject variances (0.50). So, homogeneous 
within-individual variances were found in this current study. The index of individuality of all 
subjects was found to be 0.59.  There was marked individuality with low index of 
individuality. Stratification by sex is considered when reference values are being considered.  
The index of individuality for males and females, respectively, was 0.61 and 0.56. The 
reference change values (RCVs) of urinary 8-oxodG for all subjects, males and females were, 
respectively, 53.5, 45.1 and 59.9%.  
  Mean (SD) urine 8-oxodG concentration in 11 cancer patients was 2.71 (0.78) 
nmol/mmol creatinine, which was significantly (P<0.0001) higher than in the healthy subjects. 
4. Discussion 
Urine 8-oxodG has been represented and used as a biomarker of oxidation-induced 
DNA damage [2,3,5-9,15-18]. However, 8-oxodG in urine originates not from repair of 
oxidized DNA, but most probably from oxidation-induced modifications to the nucleotide 
pool [15]. As such, urine 8-oxodG represents a sensitive, stable and specific marker of 
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oxidative stress at the whole body level [2-9,19]. Using urine as a sample eliminates the 
requirement for DNA extraction and 8-oxodG release from DNA, with its associated 
problems and errors [2,8,20], and testing urine simplifies the assay in other ways also. To 
elaborate briefly, 8-oxodG molecules in urine are freely dispersed in the liquid matrix. 
Therefore, it is not necessary to perform digestion or solid phase extraction before 
introducing the sample into the HPLC unit. The near 100% recovery of 8-oxodG in the 
method described reflects this, and means that an isotopic internal standard is not needed, as 
it is when there is a likelihood of loss during extensive sample workup and extraction. 
Furthermore, although other oxidized bases may be present in urine (the main one being 
deoxyguanine (dG)), good HPLC separation prevents their interference. Under the HPLC 
conditions used, dG elutes at ~4min (data not shown), far away from 8-oxodG, which elutes 
at 8.5min. Therefore, in the eluate of interest (~8.5min) no dG is present be oxidized to 8-
oxodG during electrospray ionization. If dG is of interest to measure, it is a simple matter to 
allow the 4min eluate to enter the spectrometer for measurement, but this still will not cause 
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interference with 8-oxodG measurement (or vice versa) because of their distinctly different 
elution times. 
In the method described, the column used is designed to elute with high flow rate 
while avoiding increased back-pressure. Therefore, after elution of the peak of interest,  the 
flow rate can be increased to clean the column, making isocratic elution feasible, and a very 
reproducible chromatogram is obtained. By programming only the LC column eluate 
containing the 8-oxodG to enter the mass spectrometer, contamination is minimized and the 
life of the detector is not compromised. In this way urine clean-up can be omitted, saving 
both sample handling time and cost. The run time for one sample in the current assay was 
16min, including the column washout time. The effectiveness of peak separation and on-line 
cleaning was checked by neat urine injection (without using the spectrometer) with 
simultaneous monitoring of signals from electro-chemical and photo-diode array detectors 
(results not shown). No marked increase of back-pressure or peak distortion was observed 
even after performing >300 sample injections.  
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Several methods for urine 8-oxodG measurement exist (immunoassays, HPLC with 
electrochemical detection, as well as LC-MS/MS methods), and results have been reported in 
various units, including ng/dl, nmol/l, nmol/24h, ng/mg creatinine and nmol/mmol creatinine 
[see Table 3 and references 19-33]. This makes it difficult to compare results of different 
studies. To compensate for the highly variable water content of urine, urine 8-oxodG results 
should be concentration standardized, i.e. expressed relative to urine creatinine. Methods that 
employ LC-MS/MS are preferred due to the high sensitivity and specificity of this technique 
[8,15,21-30,33]. Immunoassay gives markedly higher results due to lack of specificity of the 
antibodies, and immunodetection methods are not recommended [15,18,30,31]. Furthermore, 
urea, abundant in urine, has recently been found to cross-react in immunoassay methods [32].  
In published LC-MS/MS methods for 8-oxodG, sample pre-treatment requires the use 
of an internal standard to maintain satisfactory recovery and low LOD.  In the method 
presented here, recovery was excellent, though it is noted that the true LOD (of 2.3 nM) was 
higher than in some published methods [Table 3]. However, absolute 8-oxodG concentrations 
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in normal urine are in the range of 3.0-40 nM, indicating that the true LOD of 2.3 nM of this 
method is acceptable [24,30,34,35].  
Table 3 near here 
When the urinary 8-oxodG results (as nmol/mmol creatinine) of this current 
investigation of 51 healthy Chinese adults were analyzed by gender, males had slightly but 
significantly higher levels than females. The reasons are not clear, but it is noted that most of 
female subjects were pre-menopausal. Pre-menopausal females have lower iron status than 
men, and women also tend to have higher plasma ascorbic acid concentrations and lower 
metabolic rate than men [36,37]. Together, these factors are likely to lower oxidative stress in 
women. We saw no age-related increases in urine 8-oxodG in this study, but this may have 
been because subjects were all apparently healthy and no subjects of advanced age were 
recruited. Further study is needed to see if this biomarker is affect by age per se, or if healthy 
elderly subjects retain similar values to healthy younger subjects.   
The issue of what magnitude of change can be expected to occur normally in urine 8-
oxodG has not been well studied. Data presented indicate that a change of ~50% in urine 8-
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oxodG can be expected to occur normally in an individual. The high and random variation 
observed in the level of urinary 8-oxodG within and between individuals may be explained 
by genetic polymorphisms of the genes such as CYP2E1 and GSTT1 genotypes involved in 
metabolism and detoxification [37,38], to differences in antioxidant status as well as the 
lifestyle of the individuals, and even to psychological and occupational stresses such as 
physical labour and day-night shift work [39-42]. 
Regardless of the cause, the wide intra-individual variation means that, in clinical 
study of individuals, a series of measurements is needed to track pathological or treatment- 
related effects on oxidative stress. However, there was no evidence of a diurnal or any 
common pattern of change in urine 8-oxodG within a day or between days in healthy adults. 
This indicates that time of sampling is not critical. Furthermore, data indicate that a sustained 
trend of change in urine 8-oxodG concentration in an individual or group is likely to be 
caused by a change in oxidative stress, and very unlikely to be caused by normal biological 
variation. To fully validate a biomarker for clinical use, it must be shown to be different in 
healthy vs. diseased subjects, and to relate to stage of disease. Such evaluation is outside the 
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scope of this methodological and biological variation study, but our very preliminary data on 
cancer patients (who could be expected to be in a state of increased oxidative stress) showed 
they had significantly higher urine 8-oxodG than the healthy subjects studied. However, it 
must be noted that these subjects were not age or sex matched to the healthy group, and the 
number was very small. Results need to be confirmed in larger study.   
In conclusion, the urine 8-oxodG LC-MS/MS method presented does not require 
sample pre-treatment for 8-oxodG extraction, or the use of an internal standard, or gradient 
LC elution. It has the advantages of speed, simplicity and lower cost when compared to LC-
MS/MS methods that do require these steps, and it demonstrates high specificity, precision 
and recovery. Within-day and between-day variations in urine 8-oxodG in healthy adults are 
wide but random, and no differences at the group level were seen over the course of a single 
day or over five consecutive days. 
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Figure Legends 
Fig. 1. Test on ion suppression effect: under multiple reaction monitoring mode (m/z 284 → 
168 amu): (a) mobile phase (20µl) was injected during infusion of aqueous 8-oxodG (3.2µM) 
and no ion suppression occurred; (b) neat urine (20µl) was injected with infusion of 8-oxodG 
and strong ion suppression, due to compounds present in  urine matrix, occurred at 2.7-
3.7min; (c) neat urine (25µl) spiked with 8-oxodG (14.1nM in urine) in a normal 
chromatographic run, 8-oxodG elution peak at 8.0-8.8min. 
Fig. 2. Typical calibration curve of the assay over 8-oxodG concentration 7 to 113nM. 
Fig. 3. Test on absolute limit of detection of 8-oxodG with chromatograms showing: (a) 
water (25µl) injected to observe the baseline; (b) absolute LOD of 8-oxodG in water (45fmol 
injected), peak at 8.7min with S/N ratio >3. 
Fig. 4. Biological variation in creatinine-adjusted urine 8-oxodG concentrations (medians and 
error bars of ranges) in samples from 23 healthy Chinese adults: (a) within-day variation in 
individual subjects, samples collected at 4 time-points over a single day; (b) day-to-day 
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variation in individual subjects, samples collected at the same time of day for 5 consecutive 
days. 
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Table 1. Precision, recovery and accuracy data. (a) Within-day (n=6 at each of three 
concentrations) and between-day (n=6 at each of three concentrations) precision; 
 (b) Recovery and accuracy were assessed at three levels (n=6 for each): recovery was 
performed in pooled urine spiked with 8-oxodG compared with same spike into water. 
Accuracy was calculated from nominal (calculated) values. 
(a) 
Nominal 
conc.(nM) 
Peak area (counts) CV 
(%) 1 2 3 4 5 6 
 Within-day precision 
        
7.1 562 522 572 552 552 552 3.0 
14.1 1142 1162 1182 1132 1162 1182 1.8 
56.5 4432 4452 4442 4462 4412 4432 0.4 
  
 Between-day precision 
        
7.1 535 536 536 501 544 540 2.9 
14.1 1155 1176 1106 1191 1170 1150 2.5 
56.5 4415 4506 4106 3981 4300 4400 4.7 
        
(b) 
Nominal 
conc. 
(nM) 
Recovery (%) Mean accuracy 
Peak area (counts) Mean 
(%) 
Absolute Relative 
1 2 3 4 5 6 (nM) (%) 
Urine          
7.1 560 580 610 630 520 610 99.8  7.35  103.5  
28.3 2280 2140 2140 2240 2200 2210 97.1  27.66  97.7  
56.5 4490 4300 4520 4470 4480 4600 101.0  56.24  99.5  
          
Water          
7.1 573 607 605 588 617 611    
28.3 2265 2225 2305 2235 2195 2275    
56.5 4605 4595 4645 4645 4565 4555    
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Table 2. Urine 8-oxodG excretion in 51 healthy Chinese adults 
 8-oxodG (nmol/mmol creatinine) 
n Mean (SD) Median(Range) 
    
All Subjects 51 1.7 (0.6) 1.7 (0.6-3.3) 
Males 26  1.9 (0.6)* 1.9 (0.7-3.3) 
Females 25 1.5 (0.6)  1.4 (0.6-2.5) 
*significantly higher than in females (p=0.027).   
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Table 3. Comparison of characteristics and analytical performance of 8-oxodG assays.  
Method Urine Sample 
Treatment 
Run Time 
Condition 
Cleaning 
Results in 
Human 
Urine  
Mean(SD) 
n = 
LOD Reference 
       
HPLC-
ESI/MS/MS 
25µl Sonication, 
centrifugation 
16min 
isocratic 
on-line 
1.7 (0.6)a 
n=51 
1.8nM or 
45fmol 
This paper 
HPLC-
ESI/MS/MS 
65µl Dilution, 
precipitation, 
redissolved 
10min 
isocratic  
* 
~0.26(0.04)a 
n=4 
2nM 
or 40fmol 
Malayappan et 
al., 2007 [21] 
HPLC-
ESI/MS/MS 
500µl SPE 25 min 
gradient 
1.8–4.2b 
n=3 
0.35fmol Sabatini et al., 
2005 [22] 
HPLC-
ESI/MS/MS 
500µl SPE 10min 
isocratic 
- 
5.59(3.34)c 
n=49 
0.024 
ng/ml or 
1.7fmol 
Hu et al., 
2004 [23] 
HPLC-
APCI/MS/MS 
15ml, 
inject 100µl 
Acidification, 
centrifugation 
15min 
isocratic  
** 
9.4(0.5)c 
n=12 
1ng/ml Pietta et al., 
2003 [24] 
HPLC-
ESI/MS/MS 
unclear Dilution, 
precipitation, 
redissolved 
40min 
isocratic 
cleaning unclear 
- 0.3nM 
or 7.5fmol 
Weimann et 
al., 2001 [25] 
HPLC-
ESI/MS/MS 
3ml SPE 20min 
gradient 
2.1c 
n=9 
0.2ng/mL 
or 7fmol 
Renner et al., 
2000 [26] 
HPLC-
ESI/MS/MS 
1ml SPE >11min 
isocratic 
20pmol/ml 20fmol Ravanat et al., 
1998 [27] 
HPLC-
ESI/MS/MS 
25µl Dilution, 
centrifugation 
51min 
gradient 
equilibrate 
25min 
28(2)nmol 
/24h 
n=20 
0.5nM or 
12.5fmol 
Weimann et 
al., 2002 [33] 
HPLC-EC 2mL SPE 20min 
isocratic 
2.08(1.23)b 
n=15 
 Chen et al., 
2005 [25] 
HPLC-EC 2ml SPE 20min 
isocratic 
1.61(0.95)a 
n=44 
 Pilger et al., 
 2002 [28] 
HPLC-EC 100 µl 2 Switching 
columns 
>1h 
isocratic 
5.65(2.77)c 
n=72 
 Yoshida et al., 
 2002 [30] 
ELISA 50 µl Antibody 
incubation 
>3h 
(batch assay) 
11.13(5.77)c 
n=72 
 Yoshida et al., 
 2002 [30] 
       
a, µmol/mol (or nmol/mmol) creatinine; b, ng/mg creatinine; c, ng/ml (or µg/l) urine; *guard column renewed 
every 100 injections and back-flush cleaning every 50 urine samples; **columns cleaned (time not stated) with 
90% methanol after each run; ELISA, enzyme-linked immunosorbent assay; EC, electro-chemical detection; 
SPE, solid phase extraction; APCI, atmospheric pressure chemical ionization. 
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Fig. 1 (a) 
 
Fig. 1 (b) 
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Fig. 1 (c) 
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Fig. 2 
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Fig. 3 (a) 
 
Fig. 3 (b) 
 

